Login to Your Account


Frequency locks on $32M series A for hearing loss drug

By Michael Fitzhugh
Staff Writer

Wednesday, April 12, 2017

Frequency Therapeutics Inc., a company working to develop a progenitor cell-activating hearing restoration therapy, has closed a $32 million series A financing led by Cobro Ventures.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription